Notably, this combination is associated with mutations in the CEBPA gene (CCAAT Enhancer Binding Protein Alpha), which serves as a favorable prognostic biomarker in CN-AML patients [23]. This evidence concerns the gene CEBPA and acute myeloid leukemia.